Integra LifeSciences (NASDAQ:IART) Reaches New 1-Year Low at $33.12

Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) shares hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $33.12 and last traded at $33.15, with a volume of 537564 shares traded. The stock had previously closed at $34.08.

Analyst Ratings Changes

Several equities research analysts have weighed in on IART shares. Truist Financial dropped their target price on Integra LifeSciences from $46.00 to $41.00 and set a "hold" rating on the stock in a research report on Friday, March 1st. StockNews.com lowered Integra LifeSciences from a "buy" rating to a "hold" rating in a research report on Friday, April 5th. Citigroup raised Integra LifeSciences from a "sell" rating to a "neutral" rating and set a $38.00 price target on the stock in a report on Wednesday, April 3rd. Finally, JMP Securities lowered their price target on Integra LifeSciences from $55.00 to $49.00 and set a "market outperform" rating on the stock in a report on Thursday, February 29th. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $44.89.

Integra LifeSciences Stock Performance

The firm's 50-day moving average price is $37.99 and its two-hundred day moving average price is $39.35. The company has a quick ratio of 2.18, a current ratio of 3.45 and a debt-to-equity ratio of 0.94. The firm has a market capitalization of $2.61 billion, a PE ratio of 39.94, a P/E/G ratio of 1.04 and a beta of 1.12.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.90 by ($0.01). The firm had revenue of $397.00 million for the quarter, compared to analyst estimates of $399.30 million. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The firm's revenue was down .3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.94 EPS. As a group, research analysts predict that Integra LifeSciences Holdings Co. will post 3.19 earnings per share for the current fiscal year.

Institutional Trading of Integra LifeSciences

Hedge funds have recently bought and sold shares of the stock. Capital Research Global Investors increased its position in shares of Integra LifeSciences by 40.1% during the 4th quarter. Capital Research Global Investors now owns 4,297,326 shares of the life sciences company's stock worth $187,149,000 after purchasing an additional 1,228,996 shares in the last quarter. Deerfield Management Company L.P. Series C acquired a new stake in Integra LifeSciences in the 3rd quarter valued at about $43,034,000. Select Equity Group L.P. acquired a new stake in Integra LifeSciences in the 4th quarter valued at about $47,199,000. Norges Bank acquired a new stake in Integra LifeSciences in the 4th quarter valued at about $39,872,000. Finally, Assenagon Asset Management S.A. acquired a new stake in Integra LifeSciences in the 3rd quarter valued at about $25,443,000. 84.78% of the stock is owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.